دورية أكاديمية
أعرض في EDS

Papaverine: A Miraculous Alkaloid from Opium and Its Multimedicinal Application.

التفاصيل البيبلوغرافية
العنوان: Papaverine: A Miraculous Alkaloid from Opium and Its Multimedicinal Application.
المؤلفون: Ashrafi S; Department of Pharmaceutical Chemistry, University of Dhaka, Dhaka 1000, Bangladesh., Alam S; Department of Pharmaceutical Chemistry, University of Dhaka, Dhaka 1000, Bangladesh.; Drugs and Toxins Research Division, BCSIR Laboratories Rajshahi, Bangladesh Council of Scientific and Industrial Research, Rajshahi 6206, Bangladesh., Sultana A; Department of Pharmaceutical Chemistry, University of Dhaka, Dhaka 1000, Bangladesh., Raj A; Department of Pharmaceutical Chemistry, University of Dhaka, Dhaka 1000, Bangladesh., Emon NU; Department of Pharmacy, Faculty of Science and Engineering, International Islamic University Chittagong, Chittagong 4318, Bangladesh.; Department of Chemistry and Biochemistry, Cell and Molecular Biology Program, University of Arkansas, Fayetteville, AR 72701, USA., Richi FT; Department of Pharmaceutical Chemistry, University of Dhaka, Dhaka 1000, Bangladesh., Sharmin T; Department of Pharmaceutical Chemistry, University of Dhaka, Dhaka 1000, Bangladesh., Moon M; Department of Pathology, College of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea., Park MN; Department of Pathology, College of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea., Kim B; Department of Pathology, College of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea.
المصدر: Molecules (Basel, Switzerland) [Molecules] 2023 Mar 31; Vol. 28 (7). Date of Electronic Publication: 2023 Mar 31.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 100964009 Publication Model: Electronic Cited Medium: Internet ISSN: 1420-3049 (Electronic) Linking ISSN: 14203049 NLM ISO Abbreviation: Molecules Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, c1995-
مواضيع طبية MeSH: COVID-19* , Alkaloids*/pharmacology , Benzylisoquinolines*, Humans ; Papaverine/pharmacology ; Opium ; SARS-CoV-2
مستخلص: The pharmacological actions of benzylisoquinoline alkaloids are quite substantial, and have recently attracted much attention. One of the principle benzylisoquinoline alkaloids has been found in the unripe seed capsules of Papaver somniferum L. Although it lacks analgesic effects and is unrelated to the compounds in the morphine class, it is a peripheral vasodilator and has a direct effect on vessels. It is reported to inhibit the cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) phosphodiesterase in smooth muscles, and it has been observed to increase intracellular levels of cAMP and cGMP. It induces coronary, cerebral, and pulmonary artery dilatation and helps to lower cerebral vascular resistance and enhance cerebral blood flow. Current pharmacological research has revealed that papaverine demonstrates a variety of biological activities, including activity against erectile dysfunction, postoperative vasospasms, and pulmonary vasoconstriction, as well as antiviral, cardioprotective, anti-inflammatory, anticancer, neuroprotective, and gestational actions. It was recently demonstrated that papaverine has the potential to control SARS-CoV-2 by preventing its cytopathic effect. These experiments were carried out both in vitro and in vivo and require an extensive understanding of the mechanisms of action. With its multiple mechanisms, papaverine can be considered as a natural compound that is used to develop therapeutic drugs. To validate its applications, additional research is required into its precise therapeutic mechanisms as well as its acute and chronic toxicities. Therefore, the goal of this review is to discuss the major studies and reported clinical studies looking into the pharmacological effects of papaverine and the mechanisms of action underneath these effects. Additionally, it is recommended to conduct further research via significant pharmacodynamic and pharmacokinetic studies.
References: Sao Paulo Med J. 2001 Jul 5;119(4):135-7. (PMID: 11500786)
Andrologia. 2010 Feb;42(1):1-4. (PMID: 20078509)
Chem Pharm Bull (Tokyo). 2011;59(3):388-91. (PMID: 21372424)
Drug Dev Ind Pharm. 2012 Aug;38(8):912-22. (PMID: 22080854)
J Stroke Cerebrovasc Dis. 2015 Jan;24(1):41-7. (PMID: 25440359)
Interv Neurol. 2013 Oct;2(1):30-51. (PMID: 25187783)
Front Plant Sci. 2017 Jul 06;8:1172. (PMID: 28729873)
Respirology. 2007 Nov;12(6):799-806. (PMID: 17986106)
Biomed Pharmacother. 2020 Oct;130:110576. (PMID: 32768884)
BMC Complement Med Ther. 2021 Apr 12;21(1):119. (PMID: 33845836)
Neurosurg Focus. 2006 Sep 15;21(3):E12. (PMID: 17029336)
Biomol Ther (Seoul). 2021 May 1;29(3):295-302. (PMID: 33911050)
Molecules. 2021 Oct 22;26(21):. (PMID: 34770797)
Int J Rehabil Res. 2011 Mar;34(1):44-52. (PMID: 20700057)
Toxicology. 2003 Jul 15;189(1-2):1-20. (PMID: 12821279)
Int Braz J Urol. 2018 May-Jun;44(3):617-622. (PMID: 29617080)
Drug Des Devel Ther. 2016 Feb 26;10:851-9. (PMID: 27013863)
Front Endocrinol (Lausanne). 2022 Feb 24;13:800714. (PMID: 35282429)
J Surg Res. 2015 May 1;195(1):271-6. (PMID: 25676464)
Acta Biomater. 2014 Jul;10(7):3018-28. (PMID: 24704697)
Pharmacol Rep. 2021 Apr;73(2):615-628. (PMID: 33389727)
Virus Res. 2005 Aug;111(2):132-47. (PMID: 15893837)
Am J Obstet Gynecol. 2000 Jul;183(1):160-6. (PMID: 10920325)
Psychopharmacology (Berl). 2009 May;203(4):723-35. (PMID: 19066855)
Biomed Pharmacother. 2021 Nov;143:112185. (PMID: 34543985)
Arch Gynecol Obstet. 2010 Jul;282(1):11-5. (PMID: 19644697)
Invest New Drugs. 2009 Aug;27(4):289-96. (PMID: 18773143)
Urology. 2001 Apr;57(4):758-62. (PMID: 11306399)
Cell Signal. 2017 Nov;39:55-65. (PMID: 28754627)
Int J Mol Sci. 2022 Apr 22;23(9):. (PMID: 35563045)
Alzheimers Dement (N Y). 2017 Nov 11;3(4):651-657. (PMID: 29255791)
Proc Natl Acad Sci U S A. 2018 Oct 16;115(42):10756-10761. (PMID: 30201710)
Molecules. 2020 Nov 20;25(22):. (PMID: 33233775)
Acta Pharm Sin B. 2018 Sep;8(5):721-732. (PMID: 30245961)
Vascul Pharmacol. 2016 Jan;76:53-61. (PMID: 26586313)
J Mol Neurosci. 2019 May;68(1):111-119. (PMID: 30852743)
AJNR Am J Neuroradiol. 2004 Jun-Jul;25(6):1067-76. (PMID: 15205150)
Stroke. 2001 Feb;32(2):498-505. (PMID: 11157189)
Plant J. 2009 Oct;60(1):56-67. (PMID: 19500305)
J Clin Neurosci. 2002 Sep;9(5):561-5. (PMID: 12383416)
J Sex Med. 2004 Sep;1(2):128-40. (PMID: 16422967)
J BUON. 2017 Jan-Feb;22(1):112-118. (PMID: 28365943)
Surg Neurol. 1999 Jan;51(1):66-74. (PMID: 9952126)
Brain Res. 2011 Mar 4;1377:32-40. (PMID: 21211516)
Nat Neurosci. 2017 Oct;20(10):1342-1349. (PMID: 28805813)
Cells. 2022 Oct 26;11(21):. (PMID: 36359780)
Curr Obes Rep. 2019 Jun;8(2):156-164. (PMID: 30874963)
PLoS One. 2019 May 17;14(5):e0216358. (PMID: 31100066)
PLoS One. 2013 May 30;8(5):e65622. (PMID: 23738019)
Phytochemistry. 2010 Aug;71(11-12):1305-12. (PMID: 20494383)
Front Pharmacol. 2021 May 28;12:671498. (PMID: 34122096)
Biochem Biophys Res Commun. 2019 Apr 9;511(3):665-670. (PMID: 30826057)
Drug Des Devel Ther. 2018 Sep 12;12:2923-2931. (PMID: 30254422)
Nat Prod Commun. 2012 May;7(5):581-6. (PMID: 22799080)
Int J Mol Sci. 2023 Jan 23;24(3):. (PMID: 36768561)
Oxid Med Cell Longev. 2022 Feb 3;2022:2041769. (PMID: 36824615)
Neurol Res. 2009 Mar;31(2):151-8. (PMID: 19298755)
Molecules. 2017 Jul 07;22(7):. (PMID: 28686181)
Zebrafish. 2008 Dec;5(4):279-87. (PMID: 19133826)
Sci Data. 2021 Feb 26;8(1):70. (PMID: 33637768)
Neurol Res. 2007 Sep;29(6):544-50. (PMID: 17535590)
Saudi Pharm J. 2020 Dec;28(12):1777-1790. (PMID: 33424267)
Plant J. 2012 Oct;72(2):331-44. (PMID: 22725256)
Heart. 2018 Nov;104(22):1807-1809. (PMID: 30366931)
Curr Opin Anaesthesiol. 2019 Feb;32(1):72-79. (PMID: 30507678)
Daru. 2015 Feb 20;23:16. (PMID: 25890335)
Expert Opin Pharmacother. 2021 May;22(7):821-834. (PMID: 33275043)
Cochrane Database Syst Rev. 2018 Mar 19;3:CD000208. (PMID: 29552749)
Drugs. 2005;65(12):1621-50. (PMID: 16060698)
Drug Dev Res. 2018 Dec;79(8):373-382. (PMID: 30343496)
Toxicol Mech Methods. 2015;25(5):388-95. (PMID: 25980655)
Annu Rev Plant Biol. 2008;59:735-69. (PMID: 18251710)
Anticancer Res. 2019 Dec;39(12):6743-6750. (PMID: 31810939)
Neurol Sci. 2014 May;35(5):715-22. (PMID: 24297765)
Hippocampus. 2013 Aug;23(8):684-95. (PMID: 23576401)
Mult Scler. 1999 Apr;5(2):126-33. (PMID: 10335522)
Beni Suef Univ J Basic Appl Sci. 2022;11(1):47. (PMID: 35402627)
Med J Aust. 2019 Jun;210(10):469-476. (PMID: 31099420)
Cochrane Database Syst Rev. 2006 Jan 25;(1):CD000458. (PMID: 16437424)
AJNR Am J Neuroradiol. 2004 May;25(5):819-26. (PMID: 15140728)
Trends Pharmacol Sci. 2000 Dec;21(12):484-9. (PMID: 11121838)
Curr Opin Chem Biol. 2019 Oct;52:1-8. (PMID: 30682725)
J Virol. 2020 Feb 28;94(6):. (PMID: 31896588)
J Pharmacol Sci. 2020 Oct;144(2):69-75. (PMID: 32713799)
Endocrine. 2004 Mar-Apr;23(2-3):149-55. (PMID: 15146094)
Oncology. 2002;63 Suppl 2:2-10. (PMID: 12466639)
Eur Neuropsychopharmacol. 2008 May;18(5):339-63. (PMID: 17913473)
Planta. 2014 Jul;240(1):19-32. (PMID: 24671624)
Med Res Rev. 2007 Jan;27(1):108-32. (PMID: 16888749)
J Pharmacol Exp Ther. 2003 Feb;304(2):706-12. (PMID: 12538825)
J Neuroinflammation. 2019 Dec 2;16(1):246. (PMID: 31791357)
Neurocrit Care. 2005;2(2):124-32. (PMID: 16159054)
J Smooth Muscle Res. 2000 Jun;36(3):83-91. (PMID: 11086880)
Br J Clin Pharmacol. 2021 Oct;87(10):3910-3915. (PMID: 33675044)
Prog Neuropsychopharmacol. 1979;3(5-6):543-50. (PMID: 401005)
Biofactors. 2005;25(1-4):87-95. (PMID: 16873933)
Plant Cell Rep. 2019 Oct;38(10):1235-1248. (PMID: 31190213)
Br J Neurosurg. 2012 Aug;26(4):517-24. (PMID: 22303863)
Anticancer Res. 2000 Mar-Apr;20(2A):761-7. (PMID: 10810351)
Methods Enzymol. 2016;575:195-224. (PMID: 27417930)
J Urol. 2008 Apr;179(4):1411-4. (PMID: 18289563)
Molecules. 2022 Sep 14;27(18):. (PMID: 36144708)
J Pharmacol Exp Ther. 1992 Oct;263(1):194-200. (PMID: 1328605)
FEMS Microbiol Rev. 2012 May;36(3):649-62. (PMID: 22316382)
Mol Inform. 2011 Mar 14;30(2-3):181-7. (PMID: 27466772)
Talanta. 2005 May 15;66(4):1005-11. (PMID: 18970084)
Molecules. 2014 Aug 08;19(8):11846-59. (PMID: 25111025)
معلومات مُعتمدة: 27302C0038 United States ES NIEHS NIH HHS
فهرسة مساهمة: Keywords: Papaver somniferum; SARS-CoV-2; alkaloid; anticancer; antiviral; benzylisoquinoline; opium; papaverine
المشرفين على المادة: DAA13NKG2Q (Papaverine)
8008-60-4 (Opium)
0 (Alkaloids)
0 (Benzylisoquinolines)
تواريخ الأحداث: Date Created: 20230413 Date Completed: 20230414 Latest Revision: 20240615
رمز التحديث: 20240615
مُعرف محوري في PubMed: PMC10095881
DOI: 10.3390/molecules28073149
PMID: 37049912
قاعدة البيانات: MEDLINE
الوصف
تدمد:1420-3049
DOI:10.3390/molecules28073149